CN103549417A - 一种洋葱苦瓜分散片及其生产工艺 - Google Patents
一种洋葱苦瓜分散片及其生产工艺 Download PDFInfo
- Publication number
- CN103549417A CN103549417A CN201310513855.XA CN201310513855A CN103549417A CN 103549417 A CN103549417 A CN 103549417A CN 201310513855 A CN201310513855 A CN 201310513855A CN 103549417 A CN103549417 A CN 103549417A
- Authority
- CN
- China
- Prior art keywords
- onion
- parts
- dispersible tablet
- bitter gourd
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000002732 Allium cepa var. cepa Nutrition 0.000 title claims abstract description 39
- 235000009811 Momordica charantia Nutrition 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 244000078912 Trichosanthes cucumerina Species 0.000 title abstract 9
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 title abstract 9
- 239000007919 dispersible tablet Substances 0.000 title abstract 8
- 244000291564 Allium cepa Species 0.000 title 1
- 241000234282 Allium Species 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 7
- 244000302512 Momordica charantia Species 0.000 claims description 22
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 21
- 235000018365 Momordica dioica Nutrition 0.000 claims description 21
- 238000007873 sieving Methods 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 11
- 235000020985 whole grains Nutrition 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 239000011122 softwood Substances 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 235000021050 feed intake Nutrition 0.000 claims description 2
- 239000011265 semifinished product Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000000465 moulding Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000007767 bonding agent Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 240000000249 Morus alba Species 0.000 description 6
- 235000008708 Morus alba Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- -1 Phenylpropanoid Glycosides phenols Chemical class 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JQNVCUBPURTQPQ-UHFFFAOYSA-N (25R)-Inokosterone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(CO)C)CCC33O)C)C3=CC(=O)C21 JQNVCUBPURTQPQ-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-LQSBFMDOSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-LQSBFMDOSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- JQNVCUBPURTQPQ-FTWMDKANSA-N Inokosterone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CC[C@H](CO)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 JQNVCUBPURTQPQ-FTWMDKANSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- JQNVCUBPURTQPQ-XDWLXSIGSA-N inokosterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(CO)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 JQNVCUBPURTQPQ-XDWLXSIGSA-N 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000002428 insect molting hormone Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明所述的一种洋葱苦瓜分散片及其生产工艺属于保健品技术领域，其主要成分重量份是：洋葱冻干粉545份，苦瓜提取物粉145份，桑叶提取物粉110份，低取代-羟丙基纤维素150份、微晶纤维素42份，硬脂酸镁8份，乙醇适量。由于原料中有洋葱冻干粉和中药提取物粉，不适于用水作为粘合剂，本发明采用适当浓度的乙醇作为粘合剂，既能保证颗粒的成型，也能保证产品的稳定性。本发明的有益效果是：洋葱、苦瓜、桑叶进行合理配伍并制成分散片，对高血脂、高血糖人群体质的改善将起到积极和有利作用，并且携带服用方便，效果稳定。洋葱苦瓜分散片的生产工艺稳定、合理、可行，适合于工业化生产。
Description
技术领域
本发明涉及洋葱苦瓜分散片的产品配方及生产工艺粉碎、制粒、干燥、整粒、总混、压片的生产技术，属于保健品技术领域。
背景技术
高血脂，严格定义应该为血脂紊乱或血脂异常，是指人体内血清脂质的浓度水平超出了正常范围，包括血清总胆固醇(TC)水平升高，血清甘油三脂(TG)水平升高，血清高密度脂蛋白胆固醇(HDLE)水平异常减低。是心脑血管疾病的主要危险因素之一。高血脂病是随着人们生活条件的改善而来的，生活节奏快、工作压力大，平时应酬多、饮食油腻，再加上缺乏体育锻炼等都是致病因素。有些人是饮食不注意，过分高脂肪、高热量、高胆固醇的饮食，以及抽烟、喝酒等生活方式不合理而导致。另外，也跟家族遗传因素有一定的关系。健康生活方式很重要，这些不注意的人就更容易得高血脂症。不一定胖人才得，当然胖人更容易得高血脂症。高血脂症在我国已不少见，甚至儿童中也有近10％者血脂偏高。另外，国内外冠心病普查资料表明，长期睡眠不佳、精神经常紧张、忧虑及时间紧迫均能影响血脂代谢。高血脂症本身没有临床症状，这也是很多人不重视早期诊断和早期治疗的重要原因。该病对身体的损害是隐匿、逐渐、进行性和全身性的。它的直接损害是加速全身动脉粥样硬化，因为全身的重要器官都要依靠动脉供血、供氧，一旦动脉被粥样斑块堵塞，就会导致严重后果。近年来高血脂患者有向年轻化发展趋势。一般情况下，高血脂的发病率随着年龄的增加有增高的趋势，患者以45-60岁的成年人为主，其中中青年的男性较多，中年以后的女性患者也不少，就目前临床发现，年轻人也有明显增加的趋势，另外，肥胖的人也较易患上高血脂。
糖尿病，是由于机体胰岛素绝对缺乏或胰岛素作用不足而引起血糖异常升高的疾病。实际上，胰岛素不仅掌管着血糖的高低，它还是我们身体其他两大类物质：脂肪和蛋白质代谢的主要调控因素。所以在糖尿病患者中，由于胰岛素的生物调节作用发生障碍，常伴有脂质代谢的紊乱。出现脂质代谢异常。而且近年来，由于我国人民的生活水平明显提高、饮食习惯发生改变等原因，血糖与血脂同时升高者日益增多。糖尿病和高脂血症均增加了冠心病的危险性，为了避免心脑血管病的发生，糖尿病患者除了血糖控制良好外，高脂血症的治疗也是不容忽视的。引起高脂血症的原因很多，但归纳起来主要有三个方面的因素：①遗传因素；②饮食因素；③内分泌或代谢因素。大多数患者的血脂异常是由于饮食不当造成的。饮食因素在高脂血症发病中的作用比较复杂，糖类摄入过多，可影响胰岛素分泌。加速肝脏极低密度脂蛋白的合成，容易引起高甘油三酯血症。胆固醇和动物脂肪摄入过多，与高胆固醇血症的形成有关，因此饮食治疗十分重要。
在我国，改革开放以来，随着人们生活水平的不断提高，高脂血症和糖尿病和发病率呈明显上升趋势，营养素摄人过剩及日常运动量的明显减少，使成人患病率增加。动脉粥样硬化性心脑血管疾病、高血压、糖尿病等疾病占老年人死因的75％，已成为我国城市居民死亡的主要原因。随着人们对亚健康认识的深入和对自身健康状况的关注，有越来越多的人会在身体各项指标稍微偏高或正常情况下，选择服用保健食品来辅助降血脂或辅助降血糖，以达到调整身体健康状况的目的。
洋葱：洋葱为百合科植物洋葱的鳞茎，具强烈的香气；近代医学研究发现，洋葱含有硫化物、类黄酮、苯丙素酚类、甾体皂苷类、含氯化合物、前列腺素类和多糖等多种化学成分，具有消炎抑菌、防癌抗癌、利尿止泻及降血糖、降血脂、降胆固醇、降血压、抗血小板凝聚、预防心脑血管病、抗氧化、美容等多种药理作用。
苦瓜：苦瓜为葫芦科植物苦瓜的果实，性味苦、寒，可清暑涤热，明目，解毒。治热病烦渴引饮，中暑，痢疾，赤眼疼痛，痈肿丹毒，恶疮。作为食用蔬菜，资源广泛，方便易得。苦瓜中的化学成分比较复杂，比较明确的有葫芦索烷型、齐墩果烷型皂苷，以及甾醇及其苷类、生物碱类等。近年来的药理研究表明，苦瓜具有显著的药理活性，尤其是降糖、抗肿瘤和抗病毒方面的活性值得深人研究。
桑叶：桑叶为桑科植物桑的叶，性味苦甘，寒，可祛风清热，凉血明目。治风温发热，头痛，目赤，口渴，肺热咳嗽，风痹，瘾疹，下肢象皮肿。含有以下化学成分：芸香甙、槲皮素、异槲皮素、槲皮素-3-三葡萄甙、微量的β-谷甾醇、菜油甾醇、β-谷甾醇β-D-葡萄甙、蛇麻脂醇、内消旋肌醇、昆虫变态激素牛膝甾酮和蜕皮甾酮、溶血素、绿原酸。并含维生素C200～300毫克％，谷胱甘肽140～400毫克％，叶酸105微克％，5-甲酰四氢叶酸22微克％，维生素B1460微克％，维生素B2300～800微克％，腺嘌呤、胆碱、胡芦巴碱，以及铜、锌、硼、锰等微量元素。现代研究发现，桑叶具有抑制血糖值上升作用、降血压作用；降低血清总胆固醇并减少在血管内壁的沉积。
本发明人经过反复研究，并通过多次实验，对以上三种原料进行合理配伍，成功制成洋葱苦瓜分散片，充分发挥每种原料的生理作用，本品具有辅助降血脂和辅助降血糖功能，至今为止，还没有发现任何与本发明类似的工艺的报道。
发明内容
为了降低高脂血症和糖尿病和发病率，本发明提供一种洋葱苦瓜分散片，是针对高血脂、高血糖的亚健康人群，对洋葱、苦瓜、桑叶进行合理配伍，开发出一种功能性保健食品，该产品对高血脂、高血糖人群体质的改善将起到积极和有利作用。
为了实现上述目的本发明采用的技术方案是：一种洋葱苦瓜分散片，其主要成分重量份是：洋葱冻干粉545份，苦瓜提取物粉145份，桑叶提取物粉110份，低取代-羟丙基纤维素150份、微晶纤维素42份，硬脂酸镁8份，乙醇适量。由于原料中有洋葱冻干粉和中药提取物粉，不适于用水作为粘合剂，本发明采用适当浓度的乙醇作为粘合剂，既能保证颗粒的成型，也能保证产品的稳定性。
所述洋葱苦瓜分散片的生产工艺是通过对洋葱冻干粉进行粉碎，苦瓜提取物粉、桑叶提取物粉进行过筛、低取代-羟丙基纤维素、微晶纤维素、硬脂酸镁，按配方比例混匀，用一定浓度的乙醇溶液制粒，烘干后整粒，总混，压制成分散片，制成服用方便的洋葱苦瓜分散片，具体按如下步骤进行：(1)粉碎及过筛，洋葱冻干粉应先进行粉碎，并过40-120目筛，过筛后原料备用；(2)苦瓜提取物粉、桑叶提取物粉粉碎，过40-120目筛，过筛后原料备用；(3)低取代-羟丙基纤维素、微晶纤维素过40-100目筛，过筛后原料备用；(4)投料，按配方量计算各原料的实际投料量；(5)混合及制湿颗粒：将称取好各原料混合10-50分钟，使混合均匀，加入60-95％乙醇适量制软材，过12-30目筛制湿颗粒；(6)烘干，制得湿颗粒在烘箱中，30℃-60℃干燥3-5小时；(7)整粒和总混，过12-30目筛整粒，加入硬脂酸镁混合均匀，得干颗粒；(8)压片：半成品检测后，将颗粒压制成分散片，片重0.4-1.2g／片。
质控指标：总黄酮以芦丁计≥1.0g／100g。
本发明的有益效果是：洋葱、苦瓜、桑叶进行合理配伍并制成分散片，对高血脂、高血糖人群体质的改善将起到积极和有利作用，并且携带服用方便，效果稳定。洋葱苦瓜分散片的生产工艺稳定、合理、可行，适合于工业化生产。
具体实施方式
下面结合具体实施方式进一步加以说明。
实施例1：洋葱冻干粉应先进行粉碎，并过60目筛，过筛后原料备用。苦瓜提取物粉、桑叶提取物粉均过60目筛，未过筛粗颗粒应进行粉碎，过筛后原料备用。低取代-羟丙基纤维素、微晶纤维素过40目筛，过筛后原料备用。按配方量计算各原料的实际投料量。将称取好各原料混合50分钟，使均匀，加入60％乙醇适量制软材，过30-目筛制湿颗粒，制得湿颗粒在烘箱中，60℃干燥3小时。过12目筛整粒，加入硬脂酸镁混合均匀，得干颗粒。将颗粒压制成分散片，片重0.4g／片。
实施例2：洋葱冻干粉应先进行粉碎，并过80目筛，过筛后原料备用。苦瓜提取物粉、桑叶提取物粉均过60目筛，未过筛粗颗粒应进行粉碎，过筛后原料备用。低取代-羟丙基纤维素、微晶纤维素过60目筛，过筛后原料备用。按配方量计算各原料的实际投料量。将称取好各原料混合20分钟，使均匀，加入80％乙醇适量制软材，过20目筛制湿颗粒，制得湿颗粒在烘箱中，60℃干燥5小时。过30目筛整粒，加入硬脂酸镁混合均匀，得干颗粒。将颗粒压制成分散片，片重0.8g／片。
实施例3：洋葱冻干粉应先进行粉碎，并过100目筛，过筛后原料备用。苦瓜提取物粉、桑叶提取物粉均过60目筛，未过筛粗颗粒应进行粉碎，过筛后原料备用。低取代-羟丙基纤维素、微晶纤维素过100目筛，过筛后原料备用。按配方量计算各原料的实际投料量。将称取好各原料混合40分钟，使均匀，加入80％乙醇适量制软材，过12目筛制湿颗粒，制得湿颗粒在烘箱中，40℃干燥3-5小时。过30目筛整粒，加入硬脂酸镁混合均匀，得干颗粒。将颗粒压制成分散片，片重1.2g／片。
洋葱苦瓜分散片的服用方法：一次1粒，日服2次。
洋葱苦瓜分散片的疗效：本产品已经服用近百例，经随访65例，其中高血脂人群体质改善的35例，高血糖人群体质改善的30例，无效0例。从以上分析来看，洋葱苦瓜分散片可达到对高血脂、高血糖人群体质的改善将起到积极和有利作用的目的。
最后应说明的是：显然，上述实施例仅仅是为清楚地说明本发明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动，由此所引伸出的显而易见的变化或变动仍处于本发明的保护范围之中。
Claims (3)
1.一种洋葱苦瓜分散片，特征是其主要成分重量份是：洋葱冻干粉545份，苦瓜提取物粉145份，桑叶提取物粉110份，低取代-羟丙基纤维素150份、微晶纤维素42份，硬脂酸镁8份，乙醇适量。
2.根据权利要求1所述的一种洋葱苦瓜分散片，其特征是采用适当浓度的乙醇作为粘合剂。
3.如权利要求1所述洋葱苦瓜分散片的生产工艺，特征是所述洋葱苦瓜分散片的生产工艺按如下步骤进行：(1)粉碎及过筛，洋葱冻干粉应先进行粉碎，并过40-120目筛，过筛后原料备用：(2)苦瓜提取物粉、桑叶提取物粉粉碎，过40-120目筛，过筛后原料备用；(3)低取代-羟丙基纤维素、微晶纤维素过40-100目筛，过筛后原料备用；(4)投料，按配方量计算各原料的实际投料量；(5)混合及制湿颗粒：将称取好各原料混合10-50分钟，使混合均匀，加入60-95％乙醇适量制软材，过12-30目筛制湿颗粒；(6)烘干，制得湿颗粒在烘箱中，30℃-60℃干燥3-5小时；(7)整粒和总混，过12-30目筛整粒，加入硬脂酸镁混合均匀，得干颗粒；(8)压片：半成品检测后，将颗粒压制成分散片，片重0.4-1.2g／片。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310513855.XA CN103549417B (zh) | 2013-10-28 | 2013-10-28 | 一种洋葱苦瓜分散片及其生产工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310513855.XA CN103549417B (zh) | 2013-10-28 | 2013-10-28 | 一种洋葱苦瓜分散片及其生产工艺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103549417A true CN103549417A (zh) | 2014-02-05 |
| CN103549417B CN103549417B (zh) | 2016-07-06 |
Family
ID=50003924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310513855.XA Expired - Fee Related CN103549417B (zh) | 2013-10-28 | 2013-10-28 | 一种洋葱苦瓜分散片及其生产工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103549417B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107929579A (zh) * | 2017-11-17 | 2018-04-20 | 张国发 | 一种天然植物降糖剂 |
| CN108578556A (zh) * | 2018-07-20 | 2018-09-28 | 陕西富捷药业有限公司 | 一种降血糖降血脂的保健品及其制备方法 |
| CN112121114A (zh) * | 2020-11-04 | 2020-12-25 | 新疆华圣元医药科技有限公司 | 一种具有辅助降血脂作用的药物组合物及其制剂 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1394623A (zh) * | 2001-07-10 | 2003-02-05 | 北京双鹤现代医药技术有限责任公司 | 一种调节血糖的保健食品及其制备方法 |
| CN102727586A (zh) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | 预防和治疗糖尿病的组合物 |
| CN103083470A (zh) * | 2013-01-28 | 2013-05-08 | 汤臣倍健股份有限公司 | 辅助降血糖的苦瓜葛根片 |
| CN103168882A (zh) * | 2011-12-26 | 2013-06-26 | 镇江市丹徒区南山溪园茶叶专业合作社 | 一种有益降血糖和减缓糖尿病并发症的保健茶 |
-
2013
- 2013-10-28 CN CN201310513855.XA patent/CN103549417B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1394623A (zh) * | 2001-07-10 | 2003-02-05 | 北京双鹤现代医药技术有限责任公司 | 一种调节血糖的保健食品及其制备方法 |
| CN102727586A (zh) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | 预防和治疗糖尿病的组合物 |
| CN103168882A (zh) * | 2011-12-26 | 2013-06-26 | 镇江市丹徒区南山溪园茶叶专业合作社 | 一种有益降血糖和减缓糖尿病并发症的保健茶 |
| CN103083470A (zh) * | 2013-01-28 | 2013-05-08 | 汤臣倍健股份有限公司 | 辅助降血糖的苦瓜葛根片 |
Non-Patent Citations (1)
| Title |
|---|
| 周玲: "洋葱药用与膳方", 《东方食疗与保健》, no. 02, 1 February 2006 (2006-02-01) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107929579A (zh) * | 2017-11-17 | 2018-04-20 | 张国发 | 一种天然植物降糖剂 |
| CN108578556A (zh) * | 2018-07-20 | 2018-09-28 | 陕西富捷药业有限公司 | 一种降血糖降血脂的保健品及其制备方法 |
| CN112121114A (zh) * | 2020-11-04 | 2020-12-25 | 新疆华圣元医药科技有限公司 | 一种具有辅助降血脂作用的药物组合物及其制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103549417B (zh) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103355555B (zh) | 一种蛋鸡产蛋高峰期饲料及其制备方法 | |
| CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
| CN102488281B (zh) | 一种具有降血糖作用的新型纯植物复合浓缩饮液及其制法 | |
| CN100571522C (zh) | 一种银杏养生茶及其制备方法 | |
| CN104026446A (zh) | 一种适合于高血糖人群服用的营养代餐粉及其制备方法 | |
| CN104705575A (zh) | 一种降低血糖的面条及其制备方法 | |
| CN102754710A (zh) | 降糖茶 | |
| CN104543834A (zh) | 一种具有降血糖功效的南瓜粉及其制备方法 | |
| Pai et al. | Evaluation of hypolipidemic effects of Lyciumbarbarum (Goji berry) in a murine model | |
| CN108392519A (zh) | 一种降血糖组合物及其制备和应用 | |
| CN102948749A (zh) | 洋参苦葛平唐胶囊 | |
| CN105596646A (zh) | 控制血糖及治疗血脂代谢异常的药品、保健品或食品组合物 | |
| CN103168813A (zh) | 一种红景天苦荞饼干及其制作方法 | |
| CN103549417A (zh) | 一种洋葱苦瓜分散片及其生产工艺 | |
| CN101804123B (zh) | 一种具有抗疲劳功效的植物原料组合物、其制备方法、用途及其产品 | |
| CN110326788A (zh) | 一种苦荞d-手性肌醇复合降糖压片及其制备方法 | |
| CN108578556A (zh) | 一种降血糖降血脂的保健品及其制备方法 | |
| CN102178718B (zh) | 一种用于治疗糖尿病和防治心脑血管疾病的制剂 | |
| CN105343585A (zh) | 一种玉米须泡腾片及其制备方法 | |
| CN102499366B (zh) | 调节血脂和抗疲劳的保健食品 | |
| CN103815080A (zh) | 苦荞速溶茶及其制备方法 | |
| CN104435072B (zh) | 一种具有辅助降血糖、降血脂的提取物及其制备方法 | |
| CN105815738A (zh) | 一种辅助降血糖的制品及其制备方法 | |
| CN101731624B (zh) | 复方雄蚕蛾抗衰老免疫调节保健食品及制备方法 | |
| CN103892041A (zh) | 一种雏鸭饲料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: XINJIANG CHANGKAI BIOTECHNOLOGY CO., LTD. Document name: Notification that Application Deemed to be Withdrawn |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: XINJIANG CHANGKAI BIOTECHNOLOGY CO., LTD. Document name: Notification to Pay the Fees |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160706 Termination date: 20181028 |